Affiliation: University of Genoa
- Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG)S Toma
Department of Medical Oncology, University of Genoa National Institute for Cancer Research, Italy
Anticancer Res 20:485-91. 2000..Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results...
- Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patientsS Toma
Department of Oncology, Biology and Genetics, National Institute for Cancer Research, 16132 Genova, Italy
Int J Oncol 17:991-1000. 2000..Neither the ATRA + tamoxifen nor the ATRA + tamoxifen + interferon combinations potentiated the ATRA-induced biological changes. Future studies evaluating the role of RAR-beta as a biological marker of retinoid activity are warranted...
- RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell linesS Toma
National Institute for Cancer Research, Department of Clinical and Experimental Oncology, University of Genoa, Italy
Int J Cancer 78:86-94. 1998..This retinoid antagonist seems to be a compound that exerts an anti-tumor activity but does not induce the toxic side effects of retinoids and might, therefore, be considered as a candidate for cancer therapy...
- Retinoids in lung cancer chemoprevention and treatmentS Toma
Department of Medical Oncology, University of Genova, Italy
Ann Oncol 10:S95-102. 1999..Such selective molecules may have a greater activity against lung cancer, with a more favourable toxicity profile, as recently suggested by our preliminary data on Ro 41-5253...
- Chemoprevention of tumors: the role of RAR-betaS Toma
Department of Oncology, Biology and Genetics, University of Genoa, Italy
Int J Biol Markers 18:78-81. 2003..Transitions between successive stages can be enhanced or inhibited in the laboratory by different types of agents, such activities providing the fundamental basis for chemoprevention...
- Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review)S Toma
Department of Medical Oncology, University of Genoa, National Institute for Cancer Research, 16132 Genova, Italy
Int J Oncol 15:321-37. 1999..To this end, clinical research should incorporate biological studies to allow the selection of subgroups of patients who are most likely to benefit from TAM-based treatment...